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ABSTRACT
Objective Patients with repaired tetralogy of Fallot
(TOF) experience increased rates of mortality and
morbidity in adulthood. This study was designed to
identify risk factors for death and ventricular tachycardia
(VT) in a large contemporary cohort of patients with
repaired TOF.
Methods Subjects with repaired TOF from four large
congenital heart centres in the USA, Canada and Europe
were enrolled. Clinical, ECG, exercise, cardiac magnetic
resonance (CMR) and outcome data were analysed.
Results Of the 873 patients (median age 24.4 years),
32 (3.7%) reached the primary outcome (28 deaths, 4
sustained VT; median age at outcome 38 years; median
time from CMR to outcome 1.9 years). Cox proportional-
hazards regression identiﬁed RV mass-to-volume ratio
≥0.3 g/mL (HR, 5.04; 95% CI 2.3 to 11.0; p<0.001),
LV EF z score<−2.0 (HR, 3.34; 95% CI 1.59 to 7.01;
p=0.001), and history of atrial tachyarrhythmia (HR,
3.65; 95% CI 1.75 to 7.62; p=0.001) as outcome
predictors. RV dysfunction was predictive of the outcome
similar to LV dysfunction. In subgroup analysis of 315
subjects with echocardiographic assessment of RV
systolic pressure, higher pressure (HR 1.39; 95% CI 1.19
to 1.62; p<0.001) was associated with death and
sustained VT independent of RV hypertrophy and LV
dysfunction.
Conclusions RV hypertrophy, ventricular dysfunction
and atrial tachyarrhythmias are predictive of death and
sustained VT in adults with repaired TOF. These ﬁndings
may inform risk stratiﬁcation and the design of future
therapeutic trials.
INTRODUCTION
Despite signiﬁcant advances in the early manage-
ment of tetralogy of Fallot (TOF) and 20-year sur-
vival rates exceeding 90%, residual hemodynamic
and electrophysiological abnormalities contribute to
increasing morbidity and mortality rates beginning
in the third decade of life.
1–4 Since the ﬁrst reports
of sudden death in survivors of TOF repair from
40 years ago, numerous attempts have been made to
deﬁne risk factors for adverse clinical outcomes.
56
Most reports, however, suffer from a small sample
size of patients predominantly operated in the late
1950s to the early 1970s when surgical techniques
were evolving rapidly. Furthermore, the ability to
noninvasively assess RV size and function, which are
notably affected by sequelae of TOF surgery, was
limited and imprecise.
7 A previous multicentre
cohort study identiﬁed QRS duration ≥180 ms as a
predictor of death and clinical arrhythmia in
patients with repaired TOF.
8 However, as with
other studies from that era, assessment of the RV
was imprecise. More recently, the advent of cardio-
vascular magnetic resonance (CMR) has allowed
accurate and reproducible noninvasive measure-
ments of biventricular size and function and quanti-
ﬁcation of valvular regurgitation.
9–11Several
single-centre studies have indicated that severe RV
dilatation and RV and/or LV dysfunction measured
by CMR are important risk factors for adverse clin-
ical outcomes, superseding the importance of QRS
prolongation as a predictor of outcome.
12 13 These
studies, similarly, were hampered by small sample
sizes and paucity of hard outcomes.
To overcome these limitations and to determine
risk factors for death and sustained ventricular tachy-
cardia (VT) in a large contemporary cohort of TOF
repair survivors, we have established the International
Multicenter TOF Registry (INDICATOR).
14 The
goals of this registry, which enrolled contemporarily
managed patients from four large congenital heart
centres in the USA, Canada and Europe, were to
allow risk stratiﬁcation based on clinical, ECG, exer-
cise and CMR data and to explore whether these risk
factors vary according to type of repair.
METHODS
Patients
A detailed description of the methodology of the
INDICATOR registry, including recruitment proto-
col, inclusion and exclusion criteria, data collection
and data analysis in the core laboratory has been
published.
14 Brieﬂy, participating centres identiﬁed
patients fulﬁlling the following inclusion criteria:
(1) repaired TOF; (2) CMR completed between
1997 and 2010; (3) 12-lead ECG within 1 year
from CMR; and (4) clinical follow-up ≥1 year or
occurrence of a primary outcome. Patients with
CMR data that were incomplete or not suitable for
quantitative assessment by the CMR core labora-
tory were excluded. Each participating centre
received Institutional Review or Ethical Board
approval.
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Congenital heart diseaseData collection
De-identiﬁed data were sent to the data coordinating centre,
which included a data repository, CMR core laboratory and a
statistical core centre. The registry collected data on patient
demographics (date of birth, gender, race), anatomic type of
TOF, associated anomalies, surgical and catheter interventions
and clinical outcomes. Clinical history and dates of any arrhyth-
mias were recorded, including atrial ablation prior to a docu-
mented outcome and pacemaker or deﬁbrillator implantation
after CMR.
The following diagnostic studies were sought at the time of
enrolment: CMR, ECG, ambulatory 24-h Holter monitor and
exercise stress test. One centre also collected Doppler echocar-
diographic data to quantify RV systolic pressure based on peak
velocities of the tricuspid regurgitation jet and RV outﬂow. The
ECG was analysed for heart rate and QRS duration. The 24-h
Holter monitor was analysed for atrial arrhythmia (categorised
as supraventricular tachycardia, atrial ﬁbrillation or atrial ﬂutter)
and for ventricular ectopy (deﬁned as >100 premature ventricu-
lar contractions, >20 couplets or nonsustained VT lasting
<30 s).
De-identiﬁed digital copies of the CMR examinations were
sent to the CMR core laboratory for analysis. The technical
details of the CMR imaging protocol, analysis methods and
quality assurance procedures have been published.
10 14 15
Measurements included diastolic and systolic RV and LV
volumes, mass and pulmonary regurgitation fraction.
Calculations included ventricular stroke volumes and EFs.
Measurements were adjusted to body surface area and z scores
were calculated.
Outcomes
The combined primary outcome was deﬁned as all-cause mortal-
ity (classiﬁed as sudden cardiac death, heart failure-related
death, cardiac other or non-cardiac), aborted sudden cardiac
death (deﬁned as resuscitated pulseless cardiac event) or sus-
tained VT (lasting ≥30 s or requiring cardioversion).
Participating centres updated the data coordinating centre every
6 months regarding new clinical outcomes, including periodic
reviews of available national death registries.
Statistical analysis
Categorical variables were summarised using frequencies and
percentages and compared for patients with and without the
primary outcome using Fisher’s exact test. Continuous variables
were summarised using either the mean and SD or median and
range; they were compared using the unpaired t test or
Wilcoxon rank-sum test. Cox proportional hazards regression
was used to evaluate factors associated with time from last
CMR until death, aborted sudden cardiac death or sustained
VT. Patients who did not experience the primary outcome were
censored at the time of last follow-up. Hazard ratios (HR)s are
reported with 95% CIs. Harrell’s c-index was used to quantify
how well the model discriminates between subjects who experi-
enced the outcome and those who did not. The c-index extends
the area under the receiver-operator curve (c-statistic) for binary
outcomes to the case of censored survival time data; a value of
0.5 indicates that the model has no ability to predict the
outcome, while a value of 1.0 indicates that the model perfectly
discriminates between subjects with and without the outcome.
Stepwise forward selection was used to ﬁt a multivariable
model. Once the factors most strongly associated with the
primary outcome were identiﬁed, cut points were considered
for continuous variables. Nagelkerke’sR
2 was reported for the
ﬁnal models. This value approximates the amount of variability
in the outcome explained by the factors in the model. Analyses
were repeated for the subgroups of patients with and without
RV-to-pulmonary artery (RV-PA) conduits. In order to evaluate
the relationship between RV systolic pressure and outcome, a
subgroup analysis was performed for patients in whom RV pres-
sure data were available within 1 year of the CMR. A two-sided
p value of less than 0.05 was considered to indicate statistical
signiﬁcance. Statistical analyses were performed using Stata V .12
(StataCorp, College Station, Texas, USA).
RESULTS
Study patients
Of the 1265 subjects screened for enrolment, 873 fulﬁlled entry
criteria, and thus, formed the study cohort. Their demographic,
anatomic and surgical characteristics are shown in table 1.
Selected laboratory data stratiﬁed by outcome are listed in
table 2.
Of the 873 cohort patients, 32 experienced the primary
outcome of death (n=28) or sustained VT (n=4). Median
follow-up from ﬁrst CMR was 4.2 years (15 days to 12.2 years).
Outcomes occurred from 4 days to 9.2 years (median 1.9 years)
after baseline evaluation at a median age of 38 years (1.7–
74.6 years). Of the 28 deaths (median age 41.8 years), 4 (14%)
were classiﬁed as sudden cardiac death (median age 43 years), 6
(22%) as heart failure-related (median age 53.7 years), 4 (14%)
as other cardiac (median age 38.5 years), 9 (32%) as non-cardiac
(median age 44.4 years), and 5 (28%) as unknown (median age
32 years). The median age at presentation of sustained VT was
29.3 years.
Predictors of outcomes
Multiple demographic, clinical, ECG, exercise and CMR vari-
ables were associated with the outcome on univariable analysis
(table 3). Although duration of the QRS complex on ECG was
not associated with the outcome when analysed as a continuous
variable, QRS duration ≥180 ms was an outcome predictor
(HR, 3.17; 95% CI 1.42 to 7.10; p=0.005). Importantly, com-
pared with a model that includes CMR-measured RV
mass-to-volume ratio and LV EF, the c-index of a model that
includes only QRS duration ≥180 ms was signiﬁcantly lower
(0.85 vs 0.59, p=0.001). Notably, RV end-diastolic volume and
RV/LV end-diastolic volume ratio were not associated with the
outcome whereas RV and LV EF, RV mass index, and RV
mass-to-volume ratio were strongly related to death and sus-
tained VT.
The best predictive model for death and sustained VT by mul-
tivariable analysis included RV mass-to-volume ratio ≥0.3 g/mL,
LV EF z score <−2.0 (<55% in males and <54% in females),
and history of atrial tachyarrhythmias (model c-index 0.832; R
2
0.246; table 4). Using Kaplan–Meier analysis, we found that in
patients with none of the above predictors, freedom from the
outcome was 98% at 5 and 10 years. In contrast, freedom from
the outcome at 5 and 10 years was 95% and 86%, respectively,
in patients with RV mass-to-volume ratio ≥ 0.3 g/mL; 86% and
74%, respectively, in patients with RV mass-to-volume ratio
≥0.3 g/mL and LV EF z score <−2.0; and 65% and 43%,
respectively, in patients with all three risk factors (ﬁgure 1).
Replacement of LV EF z score <−2.0 with RV EF z score
<−2.0 (<48% in males and <50% in females) resulted in only
slight decreases in the model’s c-index and R
2 values. Finally,
we found that the above risk factors were associated with the
outcome regardless of the type of death. Speciﬁcally,
248 Valente AM, et al. Heart 2014;100:247–253. doi:10.1136/heartjnl-2013-304958
Congenital heart diseasemultivariable analysis of patients who experienced cardiac death
or sustained VT (excluding those with non-cardiac and
unknown causes) found the same variables to be associated with
the primary outcome with a similar c-index of 0.826 as com-
pared with 0.832 for all outcomes. Similar ﬁndings were also
noted when the analysis was repeated in patients that experi-
enced cardiac death, excluding the four patients with sustained
VT.
Subgroup analyses
To determine whether risk factors for the outcome are the same
in patients with and without RV-PA conduits placed as part of
TOF repair, we performed additional subgroup analyses (table
4). Multivariable Cox regression analysis showed that the same
risk factors that were identiﬁed in the entire cohort were also
predictive in the 724 patients with no conduit. In contrast,
among the 149 patients with RV-PA conduit, predictors of
outcome included RV mass-to-volume ratio ≥0.5 g/mL and LV
end-systolic volume index ≥ 35 mL/m
2.
We further analysed interactions between Doppler-derived RV
pressure, RV hypertrophy and clinical outcomes among the 315
patients in whom all of these parameters were available. The
group with RV pressure data differed from those without this
information (n=558) with regard to demographics, clinical and
surgical histories, ECG, exercise and CMR parameters (see
online supplementary table 1S). Of the 302 patients with
Doppler data in the RVoutﬂow tract, 29 (10%) had a peak gra-
dient ≥50 mm Hg, 101 (33%) had a peak gradient between 20
and 49 mm Hg, and 172 (57%) had a peak gradient
<20 mm Hg. As expected, RV pressure positively correlated
with RV mass index (rs=0.33, p<0.001) and with RV
mass-to-volume ratio (rs=0.57, p<0.001). Compared with the
293 patients who did not have the outcome, those who experi-
enced death or sustained VT (n=22) had a signiﬁcantly higher
RV systolic pressure (64±27 mm Hg vs 40±18 mm Hg,
p<0.001). Multivariable analysis showed that in addition to
lower LV EF z score, both RV mass z score (HR 1.08 for every
1 SD increase; 95% CI 1.02 to 1.14; p=0.008) and RV pressure
(HR 1.39 for every 10 mm Hg increase; 95% CI 1.19 to 1.62;
p<0.001) were predictive of the outcome (table 4).
DISCUSSION
This large multicentre observational cohort study identiﬁed RV
hypertrophy, left or RV systolic dysfunction and atrial tachyar-
rhythmias as predictors of death or sustained VT in young adult
patients with repaired TOF. Moreover, we found that patients
with two or three concurrent risk factors were at a much greater
risk for poor clinical outcome as compared with those having
none or a single risk factor. Subgroup analyses showed that
patients with a conduit between the RV and the pulmonary
arteries have different risk factors than those without a conduit.
In selected patients with noninvasive data on RV pressure, both
RV hypertension and increased RV mass are independently asso-
ciated with poor outcomes despite correlations between these
variables. Also notable is the lack of association between RV
volumes and the study’s primary outcome. It is important to
note that in contrast to prior studies that focused on RV
volumes,
11–13 our study is the ﬁrst to examine the relationships
between CMR and other clinical and laboratory parameters and
hard clinical outcomes as opposed to surrogate outcomes.
In this study, we chose all-cause mortality or sustained VT as
the composite primary outcome because of their clinical
Table 1 Demographic, anatomic and surgical characteristics
Variable All patients (N=873) Outcome (death/VT) (N=32) No outcome (N=841) p Value
Median age at repair (years) 2.9 (0–57.2) 5.5 (0–40.9) 2.9 (0–57.2) 0.08
Median age at last CMR (years) 24.4 (0.2–72.3) 35.3 (0.6–72.3) 24.1 (0.2–71.6) 0.02
Time from repair to CMR (years) 21 (0–58) 26 (0–38) 21 (0–58) 0.27
Follow-up time after first CMR (years) 4.2 (0.04–12.2) 2.8 (0.04–11.2) 4.2 (0.09–12.2) 0.26
Gender, male 479 (55%) 20 (63%) 459 (55%) 0.47
Body surface area (m
2) 1.7±0.4 1.7±0.5 1.7±0.4 0.75
Diagnosis 0.001
Tetralogy of Fallot, pulmonary stenosis 725 (83%) 19 (59%) 706 (84%)
Tetralogy of Fallot, pulmonary atresia 131 (15%) 13 (41%) 118 (14%)
Tetralogy of Fallot, AV canal 17 (2%) 0 (0%) 17 (2%)
Additional cardiovascular anomaly 323 (37%) 12 (38%) 311 (37%) 1.00
Comorbidities 197 (23%) 11 (34%) 186 (22%) 0.13
Associated genetic disorder 87 (10%) 5 (16%) 82 (10%) 0.24
Prior palliative shunt 314 (36%) 19 (59%) 295 (35%) 0.008
Type of repair <0.001
Transannular patch 442 (51%) 7 (22%) 435 (52%)
RV-to-PA conduit 119 (14%) 13 (41%) 106 (13%)
Non-transannular patch 136 (16%) 5 (16%) 131 (16%)
Infundibular resection and pulmonary valvotomy 51 (6%) 1 (3%) 50 (6%)
Infundibular resection alone 29 (3%) 1 (3%) 28 (3%)
Pulmonary valvotomy alone 28 (3%) 2 (6%) 26 (3%)
Other 68 (8%) 3 (9%) 65 (8%)
Subsequent revision of repair 261 (30%) 12 (38%) 249 (30%) 0.33
Pulmonary valve replacement 315 (36%) 15 (47%) 300 (36%) 0.20
Other cardiac procedure(s) (eg, branch PA plasty) 665 (76%) 30 (94%) 635 (76%) 0.02
Data are count (percentage), mean±SD, or median (range).
AV, atrioventricular; CMR, cardiac MR; PA, pulmonary artery; VT, ventricular tachycardia.
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Congenital heart diseaseimportance. Although half of the deaths in this cohort were
classiﬁed as other or unknown, all-cause mortality is a key
outcome.
3 Furthermore, it is often difﬁcult to distinguish
between cardiac and non-cardiac death as comorbidities can be
induced or exacerbated by poor cardiac status. Our observation
that approximately half of the deaths were classiﬁed as other or
unknown is similar to the ﬁndings of Chiu et al
3 that 14 of
their 29 patients (48%) with repaired TOF died of non-cardiac
causes. Importantly, we found that the risk factors identiﬁed in
this study applied to patients regardless of the type of death.
Speciﬁcally, the same risk factors were associated with the
primary outcome when the analysis was restricted only to
those patients who experienced cardiac-related death or sus-
tained VT.
Previous studies on risk factors for adverse clinical outcomes
late after TOF repair have identiﬁed numerous predictors,
which can be divided into three broad categories: (1) patient
history (eg, older age at repair); (2) electrophysiologic markers
(eg, prolonged QRS duration); and (3) hemodynamic abnormal-
ities resulting from severe chronic pulmonary regurgitation and
other sequelae of TOF surgery (eg, ventricular dysfunc-
tion).
6 7 16 17 Although these studies provided useful insights
into risk stratiﬁcation, most were constrained by relatively small
sample sizes, reliance on surrogate outcomes, or lack of accurate
tools to evaluate RV size and function.
12 13 18–20 The import-
ance of our study is underscored by its analysis of data from a
large multicentre cohort with clinically important outcomes and
its comprehensive collection of variables from all three broad
categories. Whereas univariable analysis conﬁrmed several previ-
ously noted associations between clinical and laboratory para-
meters and adverse patient outcomes, multivariable analyses
provided new insights.
This study is the ﬁrst to identify RV hypertrophy as an inde-
pendent risk factor for death and sustained VT in patients with
repaired TOF. Speciﬁcally, patients with RV mass-to-volume
ratio ≥0.3 were more than ﬁve times more likely to experience
the outcome as compared with those with a lower ratio. Similar
ﬁndings were noted with other measures of RV hypertrophy
such as mass index and z score. To our knowledge, only one
previous study identiﬁed RV hypertrophy as a risk factor for
adverse clinical outcomes in this patient population.
12 Indeed,
most studies on the subject, including those with CMR data,
have not measured RV mass.
11 18 19 In contrast to patients with
congenital heart disease, a large body of literature documents
the strongly negative prognostic value of LV hypertrophy in
acquired conditions such as essential hypertension and dia-
betes.
21–23 Moreover, a recent study showed that increased RV
mass was associated with more than twice the risk of heart
failure or death in adult patients enrolled in the Multi-Ethnic
Study of Atherosclerosis (MESA).
24 Based on studies of the
myocardium in these and other acquired cardiovascular diseases,
it is reasonable to suspect that the increase in RV mass is due
not only to increase in myocyte volume but also due to increase
in interstitial volume with increased collagen concentration and
Table 2 Arrhythmia, exercise, and CMR data
Arrhythmia data All patients (N=873) Outcome (death/VT) (N=32) No outcome (N=841) p Value
QRS duration (ms) 146±28 (72–226) 154±32 (86–208) 145±28 (72–226) 0.08
Atrial flutter 60 (7%) 5 (16%) 55 (7%) 0.06
Atrial fibrillation 37 (4%) 10 (31%) 27 (3%) <0.001
Non-sustained ventricular tachycardia 81 (9%) 10 (31%) 71 (8%) <0.001
Prior ablation 48 (5%) 4 (13%) 44 (5%) 0.09
Permanent pacemaker 13 (1%) 0 (0%) 13 (2%) 1.00
Implantable defibrillator 45 (5%) 7 (22%) 38 (5%) <0.001
Exercise data All patients (N=551) Outcome (death/VT) (N=11) No outcome (N=540) p Value
Peak oxygen consumption (mL/kg/min) 25 (2–53) 14 (8–27) 25 (2–53) 0.001
Percent predicted peak oxygen consumption 64 (18–160) 46 (21–77) 64 (18–160) 0.003
Ventilatory anaerobic threshold (mL/kg/min) 15 (6–44) 11 (7–15) 15 (6–44) 0.004
Percent predicted ventilatory anaerobic threshold 41 (22–79) 36 (29–49) 41 (22–79) 0.12
CMR data All patients (N=873) Outcome (death/VT) (N=32) No outcome (N=841) p Value
RV end-diastolic volume index (mL/m
2) 152±49 145±42 153±50 0.34
RV end-systolic volume index (mL/m
2) 79±35 87±37 79±35 0.25
RV EF (%) 49±9 43±11 49±9 0.004
RV EF z score −1.9±2.0 −3.2±2.4 −1.9±2.0 0.005
RV mass index (g/m
2) 36±16 58±32 35±14 0.001
RV mass z score 3.6±3.0 7.6±5.8 3.4±2.7 <0.001
RV mass/volume (g/mL) 0.24±0.1 0.42±0.2 0.24±0.1 <0.001
Pulmonary regurgitation (%) 35±17 32±16 35±17 0.34
LV end-diastolic volume index (mL/m
2) 86±22 89±38 86±21 0.64
LV end-systolic volume index (mL/m
2) 37±15 44±26 36±14 0.12
LV EF (%) 58±8 53±10 58±8 0.01
LV EF z score −1.34±1.6 −2.57±2.2 −1.29±1.6 0.004
LV mass index (g/m
2) 53±19 81±53 52±16 0.008
LV mass/volume (g/mL) 0.63±0.2 0.90±0.4 0.62±0.2 0.002
RV/LV end-diastolic volume ratio 1.84±0.61 1.75±0.61 1.84±0.61 0.41
QRS duration and CMR data are presented as mean±SD (range). Exercise data are presented as median (range).
CMR, cardiac MR; VT, ventricular tachycardia.
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Congenital heart diseaseTable 3 Univariable predictors of outcome
HR 95% CI p Value C Index
Demographics and clinical variables
Gender, male 1.49 (0.72 to 3.05) 0.28 0.596
Body mass index ≥30 (kg/m
2) 1.89 (0.84 to 4.26) 0.12 0.556
Age at repair ≥7 years 2.51 (1.25 to 5.05) 0.01 0.596
Age at CMR ≥50 years 3.96 (1.77 to 8.83) 0.001 0.579
TOF with pulmonary atresia 3.34 (1.63 to 6.83) 0.001 0.636
Prior systemic-pulmonary artery shunt 2.40 (1.18 to 4.86) 0.02 0.618
RV-to-PA conduit 3.68 (1.80 to 7.49) <0.001 0.634
Atrial arrhythmia* 4.52 (2.24 to 9.13) <0.001 0.643
Ventricular arrhythmia† 2.23 (1.08 to 4.57) 0.03 0.566
ECG variables
QRS duration (ms) ↑10 1.11 (0.97 to 1.27) 0.12 0.578
QRS duration ≥180 (ms) 3.17 (1.42 to 7.10) 0.005 0.586
Exercise variables
Percent predicted peak work rate ↓5 1.28 (1.05 to 1.56) 0.02 0.735
Percent predicted peak VO2 ↓5 1.20 (1.01 to 1.43) 0.03 0.725
Percent predicted VAT ↓5 1.37 (0.81 to 2.31) 0.25 0.735
CMR variables
RV end-diastolic volume index (mL/m
2) ↑5 1.00 (0.96 to 1.03) 0.77 0.500
RV end-systolic volume index, mL/m
2) ↑5 1.03 (0.99 to 1.07) 0.15 0.609
RV EF (%) ↓5 1.36 (1.14 to 1.61) <0.001 0.710
RV mass index (g/m
2) ↑10 1.25 (1.14 to 1.36) <0.001 0.758
RV mass z score ↑1 1.12 (1.07 to 1.17) <0.001 0.769
RV mass/volume (g/mL) ↑0.1 1.50 (1.29 to 1.75) <0.001 0.774
Pulmonary regurgitation (%) ↑5 0.96 (0.86 to 1.08) 0.48 0.516
LV end-diastolic volume index (mL/m
2) ↑5 1.06 (0.98 to 1.13) 0.13 0.522
LV end-systolic volume index (mL/m
2) ↑5 1.15 (1.07 to 1.24) <0.001 0.650
LV EF (%) ↓5 1.40 (1.15 to 1.70) 0.001 0.697
LV mass index (g/m
2) ↑10 1.28 (1.19 to 1.39) <0.001 0.749
LV mass/volume (g/mL) ↑0.1 1.16 (1.07 to 1.27) <0.001 0.765
RV/LV end-diastolic volume ratio ↓1 1.32 (0.71 to 2.45) 0.39 0.575
*Defined as atrial flutter, atrial fibrillation, or supraventricular tachycardia.
†Defined >20 couplets or >100 isolated premature ventricular complexes in a 24-h period, or nonsustained VT.
CMR, cardiac MR; PA, pulmonary artery; TOF, tetralogy of Fallot; VAT, ventilatory aerobic threshold; VT, ventricular tachycardia.
Table 4 Multivariable predictors of outcome
HR 95% CI p Value C index R
2
All subjects (N=873; 32 outcomes)
Model 1
RV mass/volume ratio ≥0.30 (g/mL) 5.04 (2.30 to 11.0) <0.001 0.832 0.246
LV EF z score <−2.0 3.34 (1.59 to 7.01) 0.001
History of atrial arrhythmia 3.65 (1.75 to 7.62) 0.001
Model 2
RV mass/volume ratio ≥0.30 (g/mL) 4.17 (1.96 to 8.86) <0.001 0.781 0.215
RV EF z score <−2.0 2.59 (1.19 to 5.64) 0.02
History of atrial arrhythmia 3.61 (1.77 to 7.34) <0.001
Subjects without RV-PA conduits (N=724; 19 outcomes)
RV mass/volume ratio ≥0.30 (g/mL) 5.58 (1.99 to 15.7) 0.001 0.848 0.278
LV EF z score <−2.0 5.48 (1.96 to 15.4) 0.001
History of atrial arrhythmia 6.14 (2.36 to 16.0) <0.001
Subjects with RV-PA conduits (N=149; 13 outcomes)
RV mass/volume ratio ≥0.50 (g/mL) 9.31 (2.74 to 31.6) <0.001 0.799 0.292
LV end-systolic volume index ≥35 (mL/m
2) 5.79 (1.50 to 22.3) 0.01
Subjects with Doppler data (N=315; 22 outcomes)
RV mass z score (↑1) 1.08 (1.02 to 1.14) 0.008 0.864 0.362
LV EF z score (↓1) 1.52 (1.19 to 1.94) 0.001
RV pressure by Doppler (↑10 mm Hg) 1.39 (1.19 to 1.62) <0.001
PA, pulmonary artery.
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25 If conﬁrmed, this may be a target for future
therapies.
To further explore whether RV hypertrophy is a surrogate of RV
hypertension and to determine which parameter better predicts the
clinical outcome, we explored these questions in a subgroup of
patients with Doppler estimation of RV systolic pressure. As
expected, the two variables correlated with each other.
Unexpectedly, however, both were associated with the outcome in
multivariable analysis. These results suggest that despite a moderate
correlation between higher pressure and increased mass, each param-
eter contributes to risk through different mechanisms or that they
synergistically interact via a common pathway. We speculate that the
RV hypertrophy observed in our study results from a maladaptive
process in response to prolonged volume and/or pressure overload
leading to pathological increase in the ratio of interstitial content
(primarily collagen and ﬁbroblasts) to myocytes volume. Such mal-
adaptive pathological process has been shown in a variety of diseases
affecting the LV .
26 Additional factors such as intraventricular and
interventricular dyssynchrony may also contribute to mechanical
inefﬁciency of ventricular function and pathological hypertrophy.
From a practical perspective, the ﬁndings of our study
provide a framework for risk stratiﬁcation of patients with
repaired TOF. It remains speculative whether therapeutic inter-
ventions designed to prevent or lessen the risk factors identiﬁed
in this cohort will lead to improved clinical outcomes, including
longer life expectancy and freedom from major arrhythmias.
Possible therapeutic interventions include surgical or transcath-
eter pulmonary valve implantation prior to development of ven-
tricular dysfunction, development of RV hypertrophy or onset
of atrial tachyarrhythmias; ablation or other therapies for atrial
ﬂutter or ﬁbrillation; early intervention to decrease RV systolic
pressure (eg, catheter or surgical treatment of pulmonary artery
stenosis); and, ﬁnally, pharmacological therapy designed to
decrease diffuse myocardial ﬁbrosis.
Our study has several limitations. The cohort is restricted to
subjects who have undergone CMR; this limitation is partially
mitigated by the routine use of CMR in this patient group at
the participating centres. In addition, patients with pacemakers
or deﬁbrillators implanted before CMR were excluded.
Although we made every effort to ascertain clinical outcomes
through regular updates of the registry every 6 months and
review of national death registries, it is conceivable that some
outcomes were not recorded. Finally, the cutoff values for RV
mass-to-volume ratio reported here might not be generalisable
as measurement of RV mass may vary by technique.
In conclusion, RV hypertrophy and LV and RV dysfunction
measured by CMR, as well as atrial tachyarrhythmias predict
death and sustained VT in patients with repaired TOF. The like-
lihood of a poor outcome increases substantially when multiple
risk factors coexist. Elevated RV systolic pressure may confer an
additional risk, though the mechanism that distinguishes it from
that of RV hypertrophy requires additional study. These ﬁndings
may inform the design of future trials on therapeutic interven-
tions in this population.
Key messages
What is already known about this subject?
Patients with repaired tetralogy of Fallot (TOF) experience
increased rates of mortality and morbidity beginning in early
adulthood but the risk factors for late adverse outcomes are
poorly deﬁned.
How might this impact on clinical practice?
Our ﬁndings inform risk stratiﬁcation and clinical decisions as
well as the design of future trials on therapeutic interventions in
patients with repaired TOF.
What this study adds?
We analysed risk factors for adverse clinical outcomes in a
large, contemporarily managed cohort of young adult patients
with repaired TOF enrolled in the International Multicentre TOF
Registry (INdiCaTOR). The results uncover new risk factors for
death and sustained ventricular tachycardia, including right
ventricular hypertrophy, left and/or right ventricular dysfunction
and history of atrial tachyarrhythmias. This information informs
risk stratiﬁcation and clinical decisions in this rapidly growing
population of adult patients.
Figure 1 Kaplan–Meier curves for
the outcome ( death and sustained VT)
according to risk factors. Access the
article online to view this ﬁgure in
colour.
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